Sodium-glucose cotransporter-2 inhibitors (SGLT2is), otherwise known as gliflozins or flozins, are a relatively new group of drugs, initially approved for the treatment of type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.